Journal: Oncotarget

Article Title: Chiral platinum (II)-4-(2,3-dihydroxypropyl)- formamide oxo-aporphine (FOA) complexes promote tumor cells apoptosis by directly targeting G-quadruplex DNA in vitro and in vivo

doi: 10.18632/oncotarget.18778

Figure Lengend Snippet: (A) Complexes 1–6 and cisplatin towards six cancer-cell lines and one HL-7702 cell line for 48 h. (B) and (C) Complexes 4–6 (10 μ M) treated of BEL-7404 cells for 8.0 h at 37 °C, comparing with cisplatin (10 μ M), respectively. Pt content in whole cell (B) and in different fraction (C) were measured by ICP-MS. (D) Complexes 4–6 (2.0 μ M) induce cell senescence in BEL-7404 cells: these cells were treatment of complexes 4–6 with 2.0 μ M for 7d, and using β-galactosidase stain were examined by fluorescence microscopy (Nikon Te2000 microscope, 200×).

Article Snippet: In addition, BEL-7404 and BEL-7402 xenograft mouse models were purchased from Beijing HFK Bioscience Co., Ltd (Beijing, China, approval No. SCXK 2014-004).

Techniques: Staining, Fluorescence, Microscopy

Journal: Oncotarget

Article Title: Chiral platinum (II)-4-(2,3-dihydroxypropyl)- formamide oxo-aporphine (FOA) complexes promote tumor cells apoptosis by directly targeting G-quadruplex DNA in vitro and in vivo

doi: 10.18632/oncotarget.18778

Figure Lengend Snippet: (A) Effect of cell apoptosis of BEL-7404 treated with complexes 4–6 (10 μ M) for 24 h compared with the untreated cells. (B) Cell cycle effects of BEL-7404 cells treated with complexes 4–6 at 10 μ M for 48 h by flow cytometry. (C) and (D) The caspase-3 (C) and caspase-9 (D) protein expression was assessed by flow cytometry following treatment of BEL-7404 cells with complexes 4–6 (10 μ M) for 24 h.

Article Snippet: In addition, BEL-7404 and BEL-7402 xenograft mouse models were purchased from Beijing HFK Bioscience Co., Ltd (Beijing, China, approval No. SCXK 2014-004).

Techniques: Flow Cytometry, Expressing

Journal: Oncotarget

Article Title: Chiral platinum (II)-4-(2,3-dihydroxypropyl)- formamide oxo-aporphine (FOA) complexes promote tumor cells apoptosis by directly targeting G-quadruplex DNA in vitro and in vivo

doi: 10.18632/oncotarget.18778

Figure Lengend Snippet: (A) ΔTm data (°C) of 1.0 μ M HTG21, Pu39 and c-myc G4s and duplex DNA (F32T+H20M) treated with complexes 1–6 at 0–2.0 μ M were evaluated by RT-PCR. (B) The levels of TRF2, 53BP1, and TRF1 in BEL-7404 cells treated with complexes 4–6 at 10 μ M for 24 h were examined by Western blot. (C) The whole-cell extracts were prepared and analyzed by Western blot analysis using antibodies against TRF2, 53BP1, and TRF1. The same blots were stripped and re-probed with β-actin antibody to show equal protein loading. Western blotting bands from three independent measurements were quantified with Image J. in (B). (D) The influence of complexes 4–6 (10 μ M) on the telomerase activity of the BEL-7404 cells for 24 h. (E) The investigations of the expression of c-myc and hTERT in the BEL-7404 tumor cells when incubated with complexes 4–6 (10 μ M) for 24 h. C-myc and hTERT protein levels in BEL-7404 cells were analyzed by western blot. (F) The whole-cell extracts were prepared and analyzed by Western blot analysis using antibodies against c-myc and hTERT. The same blots were stripped and re-probed with β-actin antibody to show equal protein loading. Western blotting bands from three independent measurements were quantified with Image J. in (E). (G) qRT-PCR analysis of the expression levels of hTERT and c-myc in the BEL-7404 cells treated with complexes 4–6 (10 μ M). The BEL-7404 cells (5×10 5 ) were treated with complexes 4–6 (10 μ M) for 24 h. The total RNA in the cells was extracted and subjected to reverse transcription, followed by PCR for c-myc, hTERT, and GAPDH (control). (H) and (I) The investigations of the role of the transfections of EGFP plasmid vector (H) and c-myc plasmid vector (I) in the BEL-7404 tumor cells when incubated with complexes 4–6 (10 μ M) for 24 h. First, 2.0 μg of EGFP-carrying plasmid vector or 2.0 μg of c-myc-carrying plasmid vector was cotransfected into BEL-7404 cells using Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA). Complexes 4–6 (10 μ M) were then added, respectively, into medium at 6.0 h after transfection of c-myc plasmid. At another 24 h after treatment with complexes 4–6 (10 μ M), these cells were imaged using Nikon TE2000 (Japan) scanning fluorescent microscope or were examined by Multimodel Plate Reader with luciferase reporter gene assay kit.

Article Snippet: In addition, BEL-7404 and BEL-7402 xenograft mouse models were purchased from Beijing HFK Bioscience Co., Ltd (Beijing, China, approval No. SCXK 2014-004).

Techniques: Reverse Transcription Polymerase Chain Reaction, Western Blot, Activity Assay, Expressing, Incubation, Quantitative RT-PCR, Transfection, Plasmid Preparation, Microscopy, Luciferase, Reporter Gene Assay

Journal: Oncotarget

Article Title: Chiral platinum (II)-4-(2,3-dihydroxypropyl)- formamide oxo-aporphine (FOA) complexes promote tumor cells apoptosis by directly targeting G-quadruplex DNA in vitro and in vivo

doi: 10.18632/oncotarget.18778

Figure Lengend Snippet: (A–D) In vivo tumor growth inhibition activity of complex 6 (4.0, 8.0 mg/kg/d), and 5-FU (20 mg/kg/2 days) treated with BEL-7404 xenograft model. (E–H) In vivo tumor growth inhibition activity of complex 6 (4.0, 8.0 mg/kg/d) treated of BEL-7402 model with 4.0 and 8.0 mg/kg/d, comparing with cisplatin (2 mg/kg/2 days). (A) and (E). Changes in tumor volume between treatment groups (including complex 6 (4.0, 8.0 mg/kg/d), 5-FU (20 mg/kg/2 days) or cisplatin (2 mg/kg/2 days)) and vehicle (saline) group of BEL-7404 tumor-bearing mice and BEL-7402 tumor-bearing mice. Data of tumor growth were tracked by the mean tumor volume (mm 3 ) ± SD (n = 6) and calculated as percent TGI (tumor growth inhibition, %) values. (B and F) Relative body weight change by considering the body weight at the start of the treated group as 100%, the percent weight loss or gain was calculated on subsequent days of treatment. (C) and (G) Tumor weight between treatment groups and vehicle (saline) group of BEL-7404 tumor-bearing mice and BEL-7402 tumor-bearing mice. (***) P <0.05, (**) P <0.05, p vs vehicle control. (D) and (H) Photographs of harvested tumors from vehicle group and each treatment groups. (I) The expression protein level of TRF1, mutp53, hTERT, TRF2, c-myc, and 53BP1 were analyzed by western blot in BEL-7404 xenograft models treated with 8 mg/kg and 4 mg/kg complex 6, and 20 mg/kg 5-FU, respectively. (J) The whole-BEL-7404 xenograft model extracts were prepared and analyzed by Western blot analysis using antibodies against TRF1, mutp53, hTERT, TRF2, c-myc, and 53BP1. The same blots were stripped and re-probed with β-actin antibody to show equal protein loading. Western blotting bands from three independent measurements were quantified with Image J. in (I).

Article Snippet: In addition, BEL-7404 and BEL-7402 xenograft mouse models were purchased from Beijing HFK Bioscience Co., Ltd (Beijing, China, approval No. SCXK 2014-004).

Techniques: In Vivo, Inhibition, Activity Assay, Expressing, Western Blot

Journal: Oncotarget

Article Title: Chiral platinum (II)-4-(2,3-dihydroxypropyl)- formamide oxo-aporphine (FOA) complexes promote tumor cells apoptosis by directly targeting G-quadruplex DNA in vitro and in vivo

doi: 10.18632/oncotarget.18778

Figure Lengend Snippet: RT-qPCR array for determining mRNA levels of telomeres/telomerase-related gene expressions in BEL-7404 cells after treatment with complex 6 at 10 μ M for 24 h

Article Snippet: In addition, BEL-7404 and BEL-7402 xenograft mouse models were purchased from Beijing HFK Bioscience Co., Ltd (Beijing, China, approval No. SCXK 2014-004).

Techniques: Quantitative RT-PCR

Journal: Biomedicines

Article Title: Oncolytic Adenoviruses in Gastrointestinal Cancers

doi: 10.3390/biomedicines6010033

Figure Lengend Snippet: Preclinical research in liver cancer.

Article Snippet: ZD55-Smac , Bel-7404 SMMC7721 Huh-7 , - , Incorporation of therapeutic gene: ZD-Smac Under CMV promoter , ZD55-Smac was superior to ONYX-015 , [ ] .

Techniques: Construct, In Vitro, In Vivo, Plasmid Preparation, Control, Expressing, Inhibition, Phospho-proteomics, RNA Expression